Frontiers in Pharmacology (Sep 2022)

Cross-sectional study of the prevalence of prescription opioids misuse in French patients with chronic non-cancer pain: An update with the French version of the POMI scale

  • Nicolas Kerckhove,
  • Nicolas Kerckhove,
  • Noémie Delage,
  • Noémie Delage,
  • Célian Bertin,
  • Célian Bertin,
  • Célian Bertin,
  • Emmanuelle Kuhn,
  • Nathalie Cantagrel,
  • Caroline Vigneau,
  • Jessica Delorme,
  • Céline Lambert,
  • Bruno Pereira,
  • Chouki Chenaf,
  • Chouki Chenaf,
  • Chouki Chenaf,
  • Nicolas Authier,
  • Nicolas Authier,
  • Nicolas Authier,
  • Poma Network,
  • Debbah Abdelouahab,
  • Peyre Alexandre,
  • Simon Anna,
  • Defeuillet Catherine,
  • Wiart Catherine,
  • Sureau Christophe,
  • Vulser Cristofini Claire,
  • Bouhassira Didier,
  • Touchard Emmanuelle,
  • Collin Elisabeth,
  • Serra Eric,
  • Perez-Varlan Evelyne,
  • Mohy Frédérique,
  • Peyriere Hélène,
  • Le Borgne Jean-Marie,
  • Poinsignon Jean Paul,
  • Micallef Joëlle,
  • Dy Lénaïg,
  • Amilhaud Marlène,
  • Venard Maria,
  • Dorsner-Binard Marie,
  • Berrier Oui Marie,
  • Martial Maud,
  • Feuillet Maryline,
  • De Rijk Pablo,
  • Ginies Patrick,
  • Kieffert Patrick,
  • Giraud Pierric,
  • Aerts Raluca,
  • Le Boisselier Reynald,
  • Cauchin Sonia,
  • Pouplin Sophie,
  • Corand Virginie,
  • Perier Yannick,
  • Poujol Yves

DOI
https://doi.org/10.3389/fphar.2022.947006
Journal volume & issue
Vol. 13

Abstract

Read online

Public health issues related to chronic pain management and the risks of opioid misuse and abuse remain a challenge for practitioners. Data on the prevalence of disorders related to the use of prescribed opioids in patients suffering from chronic pain remains rather patchy, in particular because of the absence of a gold standard for their clinical assessment. We estimated the prevalence of prescription opioid misuse (POM), using a specific and validated opioid misuse scale (POMI-5F scale), in adults with chronic non-cancer pain. Nine-hundred-fifty-one (951) patients with opioids prescription and followed-up in pain clinics and addictology centers for chronic non-cancer pain (CNCP) completed the survey interview. The results suggest that 44.4% of participants have POM, accompanied by overuse (42.5%), use of opioids for effects other than analgesia (30.9%), withdrawal syndrome (65.7%), and craving (6.9%). The motivations cited for POM, apart from pain relief, were to calm down, relax and improve mood. POM was shown to be related to male sex (OR 1.52), young age (OR 2.21) and the presence of nociplastic pain (OR 1.62) of severe intensity (OR 2.31), codeine use (OR 1.72) and co-prescription of benzodiazepines (OR 1.59). Finally, despite the presence of three subgroups of misusers, no factor was associated with the intensity of misuse, reinforcing the view that distinguishing between strong and weak opioids is not appropriate in the context of use disorder. Almost half of patients with CNCP misuse their prescribed opioid. Practitioners should be attentive of profiles of patients at risk of POM, such as young, male patients suffering from severe nociplastic pain, receiving prescription for codeine and a co-prescription for benzodiazepine. We encourage French-speaking practitioners to use the POMI-5F scale to assess the presence of POM in their patients receiving opioid-based therapy.Clinical Trial Registrationclinicaltrials.gov, identifier NCT03195374

Keywords